Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esmolol beta-receptor modulation trial in cardiogenic shock patients on V-A ECMO
NL-OMON60132Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of esmolol in cardiogenic shock (2 arms), sponsored by Erasmus MC. Primary endpoint: Primary: change in heart rate at 24 hours. Started May 2024; status: recruiting.
02
Drugs
esmolol
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on NL-OMON60132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60132.